<DOC>
	<DOCNO>NCT01069692</DOCNO>
	<brief_summary>This study compare placebo 4 different dos SBR759 ass phosphate lower efficacy dialysis patient .</brief_summary>
	<brief_title>Placebo Versus SBR759 Lowering Phosphate Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Inclusion criterion : 1 . Men woman least 18 year age 2 . Stable maintenance hemodialysis 3 time per week 3 month great 3 . Controlled serum phosphate phosphatebinder therapy 4 . Patient must either stable phosphate binder dose willing stop phosphate binder therapy begin study , receive phosphate binder therapy least 4 week prior screen Exclusion criterion : 1 . Patients peritoneal dialysis 2 . Patients transplant parathyroidectomy schedule study 3 . Clinically significant GI disorder 4 . Unstable medical condition Chronic Kidney Disease 5 . Patient currently treat oral iron 6 . History hemachromatosis , ferritin &gt; 1000 ng/mL 7 . Transferrin saturation &gt; 60 % 8 . Uncontrolled hyperparathyroidism ( iPTH &gt; 84.8 pmol/L ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Hyperphosphatemia patient chronic kidney disease 3x/week hemodialysis</keyword>
</DOC>